Correlation of Angiogenesis Biomarkers with Early Metastatic Progression in NSCLC as Determined using a Multiplexed Immunoassay Kit

16 May 2013

This application note demonstrates the utility of the MILLIPLEX® map Human Angiogenesis/Growth Factor Magnetic Bead Panel 1, based on the Luminex® xMAP® bead-based multiplexed assay platform, in the analysis of 17 targets involved in the angiogenesis pathway in a cohort of 38 patients with various stages of non-small cell lung cancer (NSCLC). The objective was to determine if the MILLIPLEX® assay is able to accurately quantify known angiogenesis targets in a practical, high throughput fashion.

Links

Tags

Cell-Based AssaysCell-based assays are used to monitor the presence, quantity and activities of a desired cellular analyte including drug molecules or biomarkers. This can reveal information on cell health (apoptosis, cytotoxicity, viability and proliferation assays), cell metabolism, cell migration and cell signaling mechanisms. Find the best cell-based assay products, kits and equipment with our peer reviewed product directory: compare products, check customer reviews and receiving pricing direct from manufacturers.BiomarkersBiomarkers are biological markers which can be measured and evaluated to indicate a biological state. The use of biomarkers in research and diagnosis can indicate a normal or disease state or drug response of cells / tissues. Biomarkers include genetic markers, cell surface markers such as antigens, antibodies or receptors and secreted molecules such as cytokines. An assay system is required for identification of biomarkers. :Lung CancerLung cancer is a leading cause of cancer-related deaths worldwide, often diagnosed at an advanced stage. Research focuses on early detection, targeted therapies, and personalized treatment strategies. Explore lung cancer research and diagnostic products in our peer-reviewed product directory; compare products, check reviews, and get pricing directly from manufacturers.MetastasisAngiogenesisMagnetic Beads
Correlation of Angiogenesis Biomarkers with Early Metastatic Progression in NSCLC as Determined using a Multiplexed Immunoassay Kit